Croda’s third quarter sales grew 6.5% to £425mn (5.9% expected), when ignoring currency movements.
Growth was led by the Consumer Care business which saw a rebound in Beauty Actives and strong double-digit gains in Flavours & Fragrances.
In Life Sciences, a continued recovery in Crop Protection more than offset weakness in sales to Pharmaceutical customers.
All regions contributed positively to sales growth, except Asia, where US trade tariffs weighed on performance.
Full-year pre-tax profit guidance of £265-295mn remains unchanged.
The shares were up 3.9% in early trading.
Our view
HL view to follow.
Croda key facts
All ratios are sourced from LSEG Datastream, based on previous day’s closing values. Please remember yields are variable and not a reliable indicator of future income. Keep in mind key figures shouldn’t be looked at on their own – it’s important to understand the big picture.
This article is original Hargreaves Lansdown content, published by Hargreaves Lansdown. It was correct as at the date of publication, and our views may have changed since then. Unless otherwise stated estimates, including prospective yields, are a consensus of analyst forecasts provided by LSEG. These estimates are not a reliable indicator of future performance. Yields are variable and not guaranteed. Investments rise and fall in value so investors could make a loss.
This article is not advice or a recommendation to buy, sell or hold any investment. No view is given on the present or future value or price of any investment, and investors should form their own view on any proposed investment.